<DOC>
	<DOCNO>NCT01513408</DOCNO>
	<brief_summary>Neoadjuvant chemotherapy standard therapy management localise breast cancer , make possible evaluate tumour response . Achieving pathological complete response ( pCR ) chemotherapy important prognostic factor patient . However , patient pCR suffer relapse . In parallel , long-term prognosis patient achieve pCR poorly document , specific prognostic factor clearly identified.Preclinical clinical study argue immunogenic role chemotherapy regimen , anthracyclines , taxanes trastuzumab . By facilitate recruitment CD8 T-lymphocytes tumour bed , agent could favourably influence antitumour immune response , partially contribute efficacy . Conversely , tumour promote accumulation regulatory T-lymphocytes express Foxp3 , thus evade anti-tumour immune response , increased number regulatory T-cells associate less favourable prognosis breast cancer patient . We previously show high number CD8 T-cells associate low Foxp3 infiltration , quantify immunohistochemistry surgical specimen , associate well response well survival breast cancer patient , independently whether pCR achieve , type chemotherapy use , type breast cancer . Therefore , propose validate prospective study immunological prognostic marker large cohort patient treat neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Relevance T Lymphocytes Tumor Infiltrates CD8 Foxp3 Immune Prognostic Biomarker Breast Cancer Treated Neo Adjuvant Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>inclusion criterion 1 . Signed informed consent 2 . Social security coverage 3 . Age 18 80 year 4 . Histologically proven breast cancer , regardless histological type molecular subtype ( triple negative , hormonereceptor positive , HER2+++ ) , include inflammatory form 5 . Localised breast cancer without axillary subclavicular lymph node involvement 6 . Absence bone visceral metastasis evaluation ( bone scintigraphy , chest Xray , abdominal echocardiography CT scan thorax , abdomen pelvic area ) 7 . Treatment neoadjuvant chemotherapy ( treatment protocol physician 's discretion ) 8 . Patient amenable receive adjuvant therapy ( chemotherapy , radiotherapy , hormone therapy , target therapy ) 9 . Breast surgery ( breastsparing ) plan neoadjuvant chemotherapy exclusion criterion 1 . Metastatic breast cancer 2 . Neoadjuvant radiotherapy 3 . Patient amenable surgery 4 . Ongoing therapy type cancer 5 . Legal incapacity ( incarceration person legal guardianship ) 6 . Patient unable sign inform consent unable attend medical followup geographical , social mental reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>CD8+</keyword>
	<keyword>Foxp3</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
</DOC>